A Distinct Repertoire of Autoantibodies in Hepatocellular Carcinoma Identified by Proteomic Analysis*
暂无分享,去创建一个
Laura Beretta | David E. Misek | Christian Bréchot | S. Hanash | L. Beretta | C. Bréchot | F. Le Naour | David E Misek | F. Brichory | Samir M Hanash | François Le Naour | Franck Brichory
[1] I. Casson,et al. Antibodies to tubulin and microtubule-associated proteins. A study in diabetes mellitus, systemic lupus erythematosus, and rheumatoid arthritis. , 1991, Molecular and chemical neuropathology.
[2] D. Nelson,et al. Immune recognition of human Hsp60 by Lyme disease patient sera. , 1993, Microbial Pathogenesis.
[3] W. Caspary,et al. Clinical evaluation of autoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma. , 1998, European journal of cancer.
[4] M. Michalak,et al. Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization , 2000, Clinical and experimental immunology.
[5] S. Tsuchiya,et al. Human Monoclonal Antibodies against Cytokeratin 18 Generated from Patients with Gastric Cancer , 1989, Japanese journal of cancer research : Gann.
[6] Kate Lorig,et al. Patient Education: A Practical Approach , 1992 .
[7] E. Tan,et al. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. , 1992, The American journal of pathology.
[8] H. Bismuth,et al. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma , 1999, British Journal of Cancer.
[9] R D Kuick,et al. A two‐dimensional electrophoresis‐related laboratory information processing system: Spot matching , 1991, Electrophoresis.
[10] K. Chayama,et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis , 1993, Hepatology.
[11] Hepatitis C virus: Epidemiology and transmission , 1997, Hepatology.
[12] H. El‐Serag,et al. Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.
[13] L. Partridge,et al. The identification of endothelial cell autoantigens. , 2000, Journal of autoimmunity.
[14] T. Soussi,et al. p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.
[15] K. Trieb,et al. Serum antibodies against the heat shock protein 60 are elevated in patients with osteosarcoma. , 2000, Immunobiology.
[16] E. Chan,et al. Diversity of antinuclear antibody responses in hepatocellular carcinoma. , 1997, Journal of hepatology.
[17] P. Srivastava,et al. Calreticulin, a Peptide-binding Chaperone of the Endoplasmic Reticulum, Elicits Tumor- and Peptide-specific Immunity , 1999, The Journal of experimental medicine.
[18] Xuan Peng,et al. A Novel Cytoplasmic Protein with RNA-binding Motifs Is an Autoantigen in Human Hepatocellular Carcinoma , 1999, The Journal of experimental medicine.
[19] M. Pfreundschuh,et al. Definition of tumor-associated antigens in hepatocellular carcinoma. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[20] Imai,et al. Autoantibody to DNA topoisomerase II in primary liver cancer , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] E. Chan,et al. A cell-cycle nuclear autoantigen containing WD-40 motifs expressed mainly in S and G2 phase cells. , 1995, Biochemical and biophysical research communications.
[22] J. Bruix,et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. , 1998, Journal of hepatology.
[23] L. Old,et al. Cancer Tumor antigens. , 1997, Current opinion in immunology.
[24] David E. Misek,et al. Profiling Changes in Gene Expression during Differentiation and Maturation of Monocyte-derived Dendritic Cells Using Both Oligonucleotide Microarrays and Proteomics* , 2001, The Journal of Biological Chemistry.
[25] David E. Misek,et al. Identification of β-Tubulin Isoforms as Tumor Antigens in Neuroblastoma , 2000 .
[26] Lloyd J. Old,et al. A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.
[27] F Gharahdaghi,et al. Mass spectrometric identification of proteins from silver‐stained polyacrylamide gel: A method for the removal of silver ions to enhance sensitivity , 1999, Electrophoresis.
[28] J. Fujita,et al. Circulating Cytokeratin 8:Anti-Cytokeratin 8 Antibody Immune Complexes in Sera of Patients with Pulmonary Fibrosis , 2000, Respiration.
[29] W. van Eden,et al. Specific immunity as a critical factor in the control of autoimmune arthritis: the example of hsp60 as an ancillary and protective autoantigen. , 1995, Scandinavian journal of rheumatology. Supplement.
[30] M. Omary,et al. Mutation of human keratin 18 in association with cryptogenic cirrhosis. , 1997, The Journal of clinical investigation.
[31] Xiang-Dong Fu,et al. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. , 1993, The Journal of clinical investigation.
[32] David E. Misek,et al. Identification of beta-tubulin isoforms as tumor antigens in neuroblastoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] M Opas,et al. Calreticulin: one protein, one gene, many functions. , 1999, The Biochemical journal.
[34] K. Chayama,et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. , 1998, Journal of hepatology.
[35] A. Pestronk,et al. Anti-tubulin autoantibodies in acquired demyelinating polyneuropathies. , 1997, The Journal of infectious diseases.
[36] M. Omary,et al. Chronic hepatitis, hepatocyte fragility, and increased soluble phosphoglycokeratins in transgenic mice expressing a keratin 18 conserved arginine mutant , 1995, The Journal of cell biology.
[37] H. Lee,et al. Nuclear matrix of calreticulin in hepatocellular carcinoma. , 2000, Cancer research.
[38] Lloyd J. Old,et al. New Paths in Human Cancer Serology , 1998, The Journal of experimental medicine.
[39] A. Odén,et al. The rising incidence of hepatocellular carcinoma. , 1999, The New England journal of medicine.
[40] S. Reed,et al. Immune response to cyclin B1 in hepatocellular carcinoma , 1997, Hepatology.